Bristol Launches Zeposia For MS, Sees Advantages In The COVID-19 Environment
Executive Summary
After delaying the launch of the MS treatment due to the pandemic, Bristol now says the market is ready for a new launch. Immunology US business unit head Tina Deignan talked to Scrip about it.
You may also be interested in...
Deal Watch: Celgene CVR From BMS Buyout Falls Through
Another victim of the COVID-pandemic, Celgene's $9-per-share contingent value right tied to BMS obtaining approval of three drugs goes unrealized due to FDA travel restrictions slowing down site inspections. Clene goes public, United Therapeutics buys PRV from Y-mAbs.
2020 Drug Launches, Like Everything, Will Be Remembered For COVID-19
Gilead's Veklury for the treatment of COVID-19 was a clear commercial standout among new drugs in 2020, but cancer drugs like Seagen's Padcev and Tukysa are poised for long-term potential.
It Was Inevitable: FDA Inspection Delay Postpones BMS’s Liso-Cel Approval
Bristol Myers Squibb confirmed that approval for lisocabtagene maraleucel (liso-cel) will be delayed by the US FDA’s COVID-19-related restrictions on travel for manufacturing facility inspectors.
Need a specific report? 1000+ reports available
Buy Reports